In a number of large-scale randomized clinical trials, ACEIs, ARBs and aldosterone receptor antagonists have significantly reduced mortality in patients with chronic heart failure, partly as a result of improved myocardial fibrosis and left ventricular remodeling. This evidence concerns the gene NR3C2 and Myocardial fibrosis.